Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.

[1]  M. Iacoviello,et al.  Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistances. , 2015, World journal of clinical cases.

[2]  L. Gesualdo,et al.  The renal arterial resistance index: a marker of renal function with an independent and incremental role in predicting heart failure progression , 2014, European journal of heart failure.

[3]  M. Hellmich,et al.  Ischemic Preconditioning for Prevention of Contrast Medium–Induced Nephropathy: Randomized Pilot RenPro Trial (Renal Protection Trial) , 2012, Circulation.

[4]  Jun Guo,et al.  Pathophysiology of contrast-induced nephropathy. , 2012, International journal of cardiology.

[5]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[6]  M. Saito,et al.  Nicorandil ameliorates ischaemia‐reperfusion injury in the rat kidney , 2011, British journal of pharmacology.

[7]  I. D. de Boer,et al.  Cystatin C identifies chronic kidney disease patients at higher risk for complications. , 2011, Journal of the American Society of Nephrology : JASN.

[8]  D. Cokkinos,et al.  Iloprost Prevents Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention , 2009, Circulation.

[9]  N. Chang,et al.  Effect of nicorandil on proteinuria in well controlled hypertensive patients , 2009, Journal of hypertension.

[10]  R. Montgomery,et al.  Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide. , 2008, American journal of physiology. Renal physiology.

[11]  S. Bernstein,et al.  Meta-analysis: Effectiveness of Drugs for Preventing Contrast-Induced Nephropathy , 2008, Annals of Internal Medicine.

[12]  S. Ito,et al.  Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease , 2007, Clinical and Experimental Nephrology.

[13]  M. Arai,et al.  Nicorandil improves post-ischemic myocardial dysfunction in association with opening the mitochondrial K(ATP) channels and decreasing hydroxyl radicals in isolated rat hearts. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[14]  Aslihan Büyüköztürk Karul,et al.  Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures , 2006, Heart.

[15]  C. Becker,et al.  Pathophysiology of contrast-induced nephropathy. , 2006, The American journal of cardiology.

[16]  S. Myers,et al.  Iodinated contrast induced renal vasoconstriction is due in part to the downregulation of renal cortical and medullary nitric oxide synthesis. , 2006, Journal of vascular surgery.

[17]  P. Aspelin,et al.  Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach , 2006, Circulation.

[18]  P. Persson,et al.  Pathophysiology of contrast medium-induced nephropathy. , 2005, Kidney international.

[19]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[20]  H. Ishizaka,et al.  Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. , 2004, American heart journal.

[21]  M. Enomoto,et al.  A sol particle homogeneous immunoassay for measuring serum cystatin C. , 2004, Clinical biochemistry.

[22]  Kirk N. Garratt,et al.  Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.

[23]  S. Hou,et al.  Hospital-acquired renal insufficiency. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  W. Hillis,et al.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.

[25]  G. Dangas,et al.  The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. , 2000, Journal of the American College of Cardiology.

[26]  E. Marbán,et al.  Nicorandil , 2024, Reactions Weekly.

[27]  M. Arai,et al.  Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. , 2000, Journal of the American College of Cardiology.

[28]  K. Tsuchiya,et al.  The KATP channel opener nicorandil: Effect on renal hemodynamics in spontaneously hypertensive and Wistar Kyoto rats , 1998 .

[29]  M. Arai,et al.  Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits. , 1997, International journal of cardiology.

[30]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[31]  C. Viscoli,et al.  The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.

[32]  G. Porter.  Effects of Contrast Agents on Renal Function , 1993, Investigative radiology.

[33]  B. Brenner,et al.  Endothelium-dependent vascular responses. Mediators and mechanisms. , 1989, The Journal of clinical investigation.

[34]  N. Taira,et al.  Nicorandil as a hybrid between nitrates and potassium channel activators. , 1989, The American journal of cardiology.